Prof Alejandro Bimbo Diaz,MD retweeted
Is “moderate drinking is good for the heart” still true? New review on alcohol and cardiovascular disease: inter-organ crosstalk, microvascular dysfunction and accelerated cardiovascular ageing. Time to rethink the glass. Read more in #EHJ.
doi.org/10.1093/eurheartj/eh…
#cardiotwitter @ESC_Journals @escardio
Prof Alejandro Bimbo Diaz,MD retweeted
Fisiopatología pura.
El rol de la inflamación en la aterosclerosis.
Una delicia de artículo.
Y un orgullo por @Guio1212
watermark02.silverchair.com/…
Prof Alejandro Bimbo Diaz,MD retweeted
A simple blood count may reveal hidden plaque. In Progression of Early Subclinical Atherosclerosis, inflammation fuelled early atherosclerosis beyond LDL and blood pressure. Read more in #EHJ.
doi.org/10.1093/eurheartj/eh…
#inflammation #cardiotwitter @ESC_Journals @escardio
Prof Alejandro Bimbo Diaz,MD retweeted
💡 JAMA Insights: #AcuteVestibularSyndrome can result from peripheral vestibular pathology or a central nervous system cause, and stroke accounts for 10% to 25% of cases.
Physical examination findings including nystagmus pattern, skew deviation, the head impulse test, the general neurological examination, and gait can help distinguish peripheral from central causes and guide decisions about imaging or neurology consultation.
ja.ma/3UJcTnF
Presented at #ScientificSessions26:
In patients with type 2 diabetes and high cardiovascular risk, a systolic blood-pressure target below 120 mm Hg did not result in fewer major cardiovascular events than a target below 140 mm Hg. Full OPTIMAL-DIABETES trial results: nej.md/3UZYKCy
@AHAScience

ALT A graph from the Original Article "Intensive Blood-Pressure Lowering in Patients with Type 2 Diabetes.” The trial name, OPTIMAL-DIABETES, is in parentheses after the title. The graph shows Kaplan–Meier curves for the primary outcome. The trial results are being presented at the American Heart Association Scientific Sessions 2026. The logo of the New England Journal of Medicine is at the bottom.
Prof Alejandro Bimbo Diaz,MD retweeted
What's a key difference between early and late-onset Alzheimer's disease? (EOAD vs LOAD)
Rapid accumulation of tau @ScienceTM
science.org/doi/10.1126/scit…
Prof Alejandro Bimbo Diaz,MD retweeted
🧵 Among adults with acute #ischemic #stroke treated 4.5 to 24 hours after onset, intravenous #tenecteplase prior to EVT did not increase functional independence or reduce disability compared with EVT alone.
ja.ma/4BHGP4a
Prof Alejandro Bimbo Diaz,MD retweeted
So important - With rare exception there is not a clinically important reason to repeat CAC scoring in asymptomatic people who have received aggressive lipoprotein control @nationallipid @society_eas @ASPCardio
Prof Alejandro Bimbo Diaz,MD retweeted
Nice RCT of 300 acute LVO patients with low NIHSS 1–5, a small core, and a large penumbra randomized to thrombectomy versus best medical within 24 hours of onset.
Rate of good outcome MRS 0–1 at 90 days:
Thrombectomy: 69%
Best medical: 50%
Trial of Endovascular Therapy for Mild Stroke with Large-Vessel Occlusion
@NEJM
nejm.org/doi/full/10.1056/NE…
Prof Alejandro Bimbo Diaz,MD retweeted
🧠💊New data suggest antiplatelets may be a strong option after ischemic stroke in active cancer, with ⬇️ lower 3-month recurrence and mortality vs anticoagulation
Read more here👇
journals.sagepub.com/doi/abs…
Doctors were excited about this cholesterol drug - why did it flop in the clinic?
go.nature.com/4zrpgnq
Prof Alejandro Bimbo Diaz,MD retweeted
🫀 Can coronary atherosclerosis actually regress?
Our new randomized FLOWPROMOTE trial analysis, published TODAY in JAMA Cardiology, shows remarkable coronary plaque regression with intensive LDL-C lowering!
Atherosclerosis is not necessarily a one-way process.
📄 JAMA Cardiology:
doi.org/10.1001/jamacardio.2…
#Atherosclerosis #LDL #Cardiology #CCTA
Prof Alejandro Bimbo Diaz,MD retweeted
#STROKE: Multimodal proteogenomic evidence links higher circulating Cathepsin B to lower white matter hyperintensity burden and better cognition, while CTSB expression is reduced within lesions. ahajrnls.org/4zmnG6o
Prof Alejandro Bimbo Diaz,MD retweeted
#BloggingStroke: "The Silent Window: Risk Factors That Quietly Shape Your Brain" by Maria Daniela Orellana Zambrano. #stroke #WorldStrokeDay
ahajournals.org/do/10.1161/b…
Prof Alejandro Bimbo Diaz,MD retweeted
#MedNews: Which diet has the greatest benefits on metabolic health: Mediterranean, low-fat, or ketogenic?
A head-to-head trial compared the diets in participants with metabolically unhealthy #obesity. At the same level of weight loss, the ketogenic diet improved liver fat and other metabolic measures the most. But how will that translate in the real world?
ja.ma/4sq7RZH
Prof Alejandro Bimbo Diaz,MD retweeted
Beyond Medications: This #WorldStrokeDay, #BloggingStroke contributor @AlexVorobyevMD highlights lifestyle changes that reduce #stroke risk. ahajournals.org/do/10.1161/b…
Prof Alejandro Bimbo Diaz,MD retweeted
Researchers have developed an AI-based approach to help physicians with real-life clinical workups, starting with the patient’s chief complaint, systematically asking questions and deciding what laboratory and imaging tests to order, and then continuing the evaluation on the basis of the answers received.
Learn more this week in Science: scim.ag/3U8xn94
Prof Alejandro Bimbo Diaz,MD retweeted
🧵 #STROKE Highlights for October are here:
🌟 In mice with intracerebral hemorrhage, oral cilostazol enhanced dural lymphatic drainage, reduced hematoma volume, and improved neurological recovery. @LD_McCullough
Prof Alejandro Bimbo Diaz,MD retweeted
#FlashbackFriday !
🧠🫀In acute ICH, ~20% systolic blood pressure reduction in the first hour and ~30% by 24h (tailored to baseline) were linked to best outcomes
👉Larger reductions may diminish benefit and warrant caution
Read more here👇
journals.sagepub.com/doi/abs…
Prof Alejandro Bimbo Diaz,MD retweeted
I really admire figures that can describe a concept better than long manuscripts.
This image is from an excellent paper in Nature by Vivek Subbiah about the future of evidence-based medicine and the design of clinical trials, all inspired by the rise of artificial intelligence.
This is the era of the next generation of 'deep' medicine.
"Current paradigms must be continuously challenged by emerging technology and by all stakeholders (the new generations of scientists, physicians, the pharma industry, regulatory authorities and, most importantly, patients). Disruptive innovation should lead to every clinical site being a research site, with all necessary quality checks and research as part of the standard of care.
My personal view is that every major disease needs a ‘Moonshot’ program and every rare disease should have an ‘Operation Warp Speed’—both with clearly identified, sustainable goals to improve population health and address equity, diversity and global access to therapies.
Methodological advances and future AI-based analyses of all data will provide deep evidence to realize the goal of personalized medicine— that is, to offer the right treatment to the right patient at the right time."
The paper: nature.com/articles/s41591-0…





























